{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:36:35Z","timestamp":1791218195826,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lpm.2017.01.017","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T04:32:07Z","timestamp":1488256327000},"page":"e23-e39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"P2","title":["The cursed duet today: Tuberculosis and HIV-coinfection"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-6551","authenticated-orcid":false,"given":"Simon","family":"Tiberi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Cristina C.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-0094","authenticated-orcid":false,"given":"Giorgia","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devan","family":"Vaghela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda C. de Q.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-9726","authenticated-orcid":false,"given":"Ananna","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashaba","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Pontali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2017.01.017_bib0770","unstructured":"Global tuberculosis report 2016. WHO library cataloguing-in-publication data ISBN 978 92 4 156539 4."},{"key":"10.1016\/j.lpm.2017.01.017_bib0775","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"issue":"9924","key":"10.1016\/j.lpm.2017.01.017_bib0780","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.017_bib0785","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5588\/ijtld.15.0360","article-title":"Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV","volume":"20","author":"O\u2019Donnell","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib0790","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5588\/ijtld.14.0961","article-title":"Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia","volume":"20","author":"Heysell","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib0795","unstructured":"World health organization. Antituberculosis drug resistance in the world. Fourth global report. WHO\/HTM\/TB\/2008.394."},{"issue":"3","key":"10.1016\/j.lpm.2017.01.017_bib0800","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3201\/eid1603.091486","article-title":"Extensively drug-resistant Mycobacterium tuberculosis from aspirates. Rural South Africa","volume":"16","author":"Heysell","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib0805","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Section accessed.[15th September 2016]."},{"key":"10.1016\/j.lpm.2017.01.017_bib0815","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0820","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2011.00954.x","article-title":"British HIV association guidelines for the treatment of TB\/HIV coinfection 2011","volume":"12","author":"Pozniak","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0825","unstructured":"NICE guidelines for Tuberculosis 2016. NG33. Accessed [16th September 2016]."},{"key":"10.1016\/j.lpm.2017.01.017_bib0830","unstructured":"Centers for disease control and prevention guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection, United States 2010."},{"issue":"4 Pt 2","key":"10.1016\/j.lpm.2017.01.017_bib0835","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0840","unstructured":"Centers for disease control and prevention: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC Recommendations, United States, 2001."},{"key":"10.1016\/j.lpm.2017.01.017_bib0845","unstructured":"World health organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations of a public health approach. WHO http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1 (2016)."},{"key":"10.1016\/j.lpm.2017.01.017_bib0850","unstructured":"European centre for disease prevention and control guidelines on management of MDR and XDR tuberculosis 2011."},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib0855","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s15010-013-0478-z","article-title":"Risk factors for false-negative results of T-SPOT. TB and tuberculin skin test in extra pulmonary tuberculosis","volume":"41","author":"Lee","year":"2013","journal-title":"Infection."},{"key":"10.1016\/j.lpm.2017.01.017_bib0860","unstructured":"Health protection agency: interferon gamma release assays (IGRA) testing for Tuberculosis. Draft Interim HPA Guidance. HPA Tuberculosis Programme Board Internal HPA guidance July 2012."},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib0865","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib0870","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.017_bib0875","doi-asserted-by":"crossref","first-page":"e0161983","DOI":"10.1371\/journal.pone.0161983","article-title":"The clinical usefulness of tuberculin skin test versus interferon gamma release assays for diagnosis of latent tuberculosis in HIV patients: a meta-analysis","volume":"11","author":"Ayubi","year":"2016","journal-title":"Plos One"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib0880","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijid.2008.03.005","article-title":"A comparative study of two different methods for the detection of latent tuberculosis in HIV positive individuals in Chile","volume":"12","author":"Balcells","year":"2008","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib0885","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CMR.00042-10","article-title":"HIV and tuberculosis: a deadly human syndemic","volume":"24","author":"Kwan","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib0890","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/656282","article-title":"Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa","volume":"51","author":"Bassett","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.lpm.2017.01.017_bib0895","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1093\/infdis\/jir411","article-title":"Tuberculosis in antiretroviral treatment services in Resource- limited settings: addressing the challenges of screening and diagnosis","volume":"204","author":"Lawn","year":"2011","journal-title":"J Infect Dis."},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib0900","doi-asserted-by":"crossref","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","article-title":"Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies","volume":"8","author":"Getahun","year":"2011","journal-title":"Plos Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0905","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32832d3b6d","article-title":"Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib0910","doi-asserted-by":"crossref","first-page":"e1001067","DOI":"10.1371\/journal.pmed.1001067","article-title":"Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB\/RIF assay: a prospective study","volume":"8","author":"Lawn","year":"2011","journal-title":"Plos Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0915","series-title":"Rapid diagnosis of pulmonary and extrapulmonary tuberculosis in HIV-infected patients. Comparison of LED fluorescent microscopy and the GeneXpert MTB\/RIF assay in a district hospital in India; tuberculosis research and treatment","author":"Alvarez-Uria","year":"2012"},{"key":"10.1016\/j.lpm.2017.01.017_bib0920","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1097\/QAD.0b013e32832e05c8","article-title":"Urine Lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib0925","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/651119","article-title":"Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples","volume":"50","author":"Hassim","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib0930","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1183\/09031936.00067114","article-title":"Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area","volume":"46","author":"Capocci","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.lpm.2017.01.017_bib0935","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa0907488","article-title":"An algorithm for tuberculosis screening and diagnosis in people with HIV","volume":"362","author":"Cain","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib0940","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/13993003.00877-2015","article-title":"Tuberculosis screening using ability to provide sputum in an endemic emergency department","volume":"47","author":"Ticona","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib0945","doi-asserted-by":"crossref","first-page":"e49928","DOI":"10.1371\/journal.pone.0049928","article-title":"Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy","volume":"7","author":"Kerkhoff","year":"2012","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.017_bib0950","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1183\/13993003.01464-2015","article-title":"Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection","volume":"47","author":"Hoff","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib0955","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1086\/518234","article-title":"Clinical, immunological, and epidemiological importance of T\u00a0cell responses in HIV-infected Africans","volume":"44","author":"Rangaka","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.017_bib0960","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/QAI.0b013e31820b07ab","article-title":"Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis","volume":"56","author":"Cattamanchi","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib0965","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1183\/13993003.00264-2016","article-title":"Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy","volume":"48","author":"Edwards","year":"2016","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.017_bib0970","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200905-0692OC","article-title":"Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus","volume":"180","author":"Monkongdee","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib0975","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(07)60284-0","article-title":"Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes","volume":"369","author":"Getahun","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.017_bib0980","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1378\/chest.102.4.1040","article-title":"Yield of bronchoscopy for the diagnosis of tuberculosis inpatients with human immunodeficiency virus infection","volume":"102","author":"Kennedy","year":"1992","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.017_bib0985","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/429825","article-title":"High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania","volume":"40","author":"Mtei","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib0990","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1164\/ajrccm.162.6.2003125","article-title":"Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil","volume":"162","author":"Conde","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib0995","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1378\/chest.116.1.97","article-title":"Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis","volume":"116","author":"Riantawan","year":"1999","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib1000","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002788","article-title":"Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts","volume":"3","author":"Baba","year":"2008","journal-title":"Plos One"},{"key":"10.1016\/j.lpm.2017.01.017_bib1005","first-page":"746","article-title":"Evaluation of suspected tuberculous pleurisy: clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda","volume":"5","author":"Luzze","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/ajrccm\/148.5.1292","article-title":"Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection","volume":"148","author":"Jones","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3109\/00365548.2011.577802","article-title":"The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania","volume":"43","author":"Munseri","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00005792-199111000-00004","article-title":"Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection","volume":"70","author":"Shafer","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl. 59","key":"10.1016\/j.lpm.2017.01.017_bib1025","first-page":"PA2755","article-title":"Clinical and morphological features of HIV-associated tuberculosis","volume":"46","author":"Burynski","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib1030","unstructured":"World health organization. Policy update: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. http:\/\/www.stoptb.org\/wg\/gli\/assets\/documents\/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf (2013)."},{"key":"10.1016\/j.lpm.2017.01.017_bib1035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1473-3099(14)70733-9","article-title":"Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international,randomised, placebo-controlled trial","volume":"14","author":"Mfinanga","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.lpm.2017.01.017_bib1040","first-page":"828","article-title":"Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk","volume":"11","author":"Panjabi","year":"2007","journal-title":"Int J Tubercul Lung Dis"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib1045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/13993003.00543-2016","article-title":"Development, roll-out and impact of Xpert MTB\/RIF for tuberculosis: what lessons have we learnt and how can we do better?","volume":"48","author":"Albert","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib1050","first-page":"CD009593","article-title":"Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","volume":"1","author":"Steingart","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.lpm.2017.01.017_bib1055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1471-2334-13-507","article-title":"Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis","volume":"13","author":"Walusimbi","year":"2013","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.lpm.2017.01.017_bib1060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cid\/cir824","article-title":"The use of an automated quantitative polymerase chain reaction (Xpert MTB\/RIF) to predict the sputum smear status of tuberculosis patients","volume":"54","author":"Theron","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5588\/ijtld.13.0853","article-title":"False-positive Xpert\u00ae MTB\/RIF assays in previously treated patients: need for caution in interpreting results","volume":"18","author":"Boyles","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.lpm.2017.01.017_bib1070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"Boehme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1075","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1097\/QAI.0000000000000672","article-title":"Underestimation of the true specificity of the urine lipoarabinomannan point-of-care diagnostic assay for HIV-associated tuberculosis","volume":"69","author":"Lawn","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lpm.2017.01.017_bib1080","first-page":"CD011420","article-title":"Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults","author":"Shah","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1183\/09031936.00025711","article-title":"Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis","volume":"38","author":"Minion","year":"2011","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.017_bib1090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1473-3099(11)70251-1","article-title":"Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study","volume":"12","author":"Lawn","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(15)01092-2","article-title":"Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial","volume":"387","author":"Peter","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.017_bib1100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/651119","article-title":"Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples","volume":"50","author":"Hassim","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1105","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/QAD.0b013e328311ac4e","article-title":"Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil","volume":"22","author":"Golub","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.lpm.2017.01.017_bib1110","doi-asserted-by":"crossref","first-page":"e1001270","DOI":"10.1371\/journal.pmed.1001270","article-title":"Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis","volume":"9","author":"Suthar","year":"2012","journal-title":"Plos Med."},{"key":"10.1016\/j.lpm.2017.01.017_bib1115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1120","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib1125","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1183\/13993003.00449-2016","article-title":"Advancing global programmatic management of latent tuberculosis infection for at risk populations","volume":"47","author":"Getahun","year":"2016","journal-title":"Eur Respir J"},{"issue":"RR\u20134","key":"10.1016\/j.lpm.2017.01.017_bib1130","first-page":"1","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.lpm.2017.01.017_bib1135","unstructured":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders [Internet]. 2012. Available from: http:\/\/whqlibdoc.who.int\/publications\/2012\/9789241503006_eng_Annexes.pdf."},{"key":"10.1016\/j.lpm.2017.01.017_bib1140","unstructured":"WHO. Protocol\u00a04. Management of tuberculosis and HIV co-infection: clinical protocol for the WHO European Region \u2013 2013 Revision [Internet]. 2013. Available from: http:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/tuberculosis\/publications\/2013\/2013-revision-protocol-4.-management-of-tuberculosis-and-hiv-coinfection."},{"key":"10.1016\/j.lpm.2017.01.017_bib1145","unstructured":"CDC. Managing drug interactions in the treatment of HIV-related tuberculosis [Internet]. 2013. Available from: http:\/\/www.cdc.gov\/tb\/TB_HIV_Drugs\/default.htm."},{"key":"10.1016\/j.lpm.2017.01.017_bib1150","unstructured":"TB Care I. International standards for tuberculosis care. 3rd ed. The Hague; 2014."},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib1155","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official american thoracic society\/Centers for disease control and prevention\/Infectious diseases society of American clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4 Suppl. 3","key":"10.1016\/j.lpm.2017.01.017_bib1160","doi-asserted-by":"crossref","first-page":"19508","DOI":"10.7448\/IAS.17.4.19508","article-title":"Management of drug-resistant TB in patients with HIV co-infection","volume":"17","author":"Meintjes","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib1165","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume":"8","author":"Phillips","year":"2013","journal-title":"PloS One."},{"issue":"4","key":"10.1016\/j.lpm.2017.01.017_bib1170","first-page":"276","article-title":"Short term chemotherapy of tuberculosis. Factors affecting relapse following short-term chemotherapy [in French]","volume":"53","author":"Aber","year":"1978","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.lpm.2017.01.017_bib1175","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/QAD.0b013e3283565dd1","article-title":"Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa","volume":"26","author":"Lawn","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.lpm.2017.01.017_bib1180","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1185","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1190","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAI.0b013e31825b5e06","article-title":"Time to initiate antiretroviral therapy between 4\u00a0weeks and 12\u00a0weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study","volume":"60","author":"Manosuthi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lpm.2017.01.017_bib1200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/M14-2979","article-title":"Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis","volume":"163","author":"Uthman","year":"2015","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.lpm.2017.01.017_bib1205","doi-asserted-by":"crossref","first-page":"e0127645","DOI":"10.1371\/journal.pone.0127645","article-title":"Early versus delayed antiretroviral therapy for HIV and tuberculosis co-infected patients: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yan","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.lpm.2017.01.017_bib1210","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV) \u2013 associated tuberculous meningitis","volume":"52","author":"Torok","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1215","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1183\/09031936.00110210","article-title":"Clinical management of tuberculosis and HIV-1 co-infection","volume":"36","author":"Schutz","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1225","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001110","article-title":"Implementation and operational research: clinical impact of the Xpert MTB\/RIF assay in patients with multidrug-resistant tuberculosis","volume":"73","author":"Padayatchi","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.lpm.2017.01.017_bib1230","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis 2016 update. Geneva: World Health Organization; 2016. ISBN-13: 978-92-4-154963-9."},{"issue":"139","key":"10.1016\/j.lpm.2017.01.017_bib1235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/16000617.0080-2015","article-title":"Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials","volume":"25","author":"Moodley","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.lpm.2017.01.017_bib1240","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01249-2016","article-title":"Faster for less: the new \u201cshorter\u201d regimen for multidrug-resistant tuberculosis","author":"Sotgiu","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib1245","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":"Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort","volume":"16","author":"Carroll","year":"2012","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib1250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1183\/09031936.00142614","article-title":"The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection","volume":"45","author":"Daskapan","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.017_bib1255","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/13993003.00599-2016","article-title":"Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV","volume":"48","author":"Zuur","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1260","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1183\/13993003.00040-2016","article-title":"Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics","volume":"47","author":"Ghimire","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib1265","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1183\/13993003.01285-2015","article-title":"End TB with precision treatment!","volume":"47","author":"van der Burgt","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.017_bib1270","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1183\/13993003.00833-2016","article-title":"Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?","volume":"48","author":"Zuur","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.017_bib1275","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1183\/13993003.00986-2016","article-title":"Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients","volume":"48","author":"Sturkenboom","year":"2016","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.017_bib1280","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3201\/eid0912.020731","article-title":"Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru","volume":"9","author":"Campos","year":"2003","journal-title":"Emerg Infect Dis."},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1285","first-page":"4","article-title":"Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana","volume":"3","author":"Kenyon","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1290","doi-asserted-by":"crossref","first-page":"e82235","DOI":"10.1371\/journal.pone.0082235","article-title":"Association between HIV\/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis","volume":"9","author":"Mesfin","year":"2014","journal-title":"Plos One"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib1295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5588\/ijtld.14.0961","article-title":"Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia","volume":"20","author":"Heysell","year":"2016","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.lpm.2017.01.017_bib1300","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12879-015-1214-3","article-title":"Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe Tropical disease hospital Johannesburg, South Africa","volume":"15","author":"Umanah","year":"2015","journal-title":"BMC Infect Dis."},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/M14-2979","article-title":"Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis","volume":"163","author":"Uthman","year":"2015","journal-title":"Ann Intern Med."},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/QCO.0b013e32835ba8f9","article-title":"When to start antiretroviral therapy during tuberculosis treatment?","volume":"26","author":"Naidoo","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","article-title":"Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy","volume":"43","author":"Manosuthi","year":"2006","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"11","key":"10.1016\/j.lpm.2017.01.017_bib1320","doi-asserted-by":"crossref","first-page":"e112017","DOI":"10.1371\/journal.pone.0112017","article-title":"The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis","volume":"9","author":"Odone","year":"2014","journal-title":"Plos One."},{"issue":"11","key":"10.1016\/j.lpm.2017.01.017_bib1325","doi-asserted-by":"crossref","first-page":"e47370","DOI":"10.1371\/journal.pone.0047370","article-title":"Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review","volume":"7","author":"Arentz","year":"2012","journal-title":"Plos One."},{"issue":"12","key":"10.1016\/j.lpm.2017.01.017_bib1330","first-page":"3273","article-title":"Quantifying the impact of drug combination regimens on TB treatment efficacy and multidrug resistance probability","volume":"70","author":"Lin","year":"2015","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"10.1016\/j.lpm.2017.01.017_bib1335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/QAI.0000000000000221","article-title":"Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study","volume":"67","author":"O\u2019Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"8","key":"10.1016\/j.lpm.2017.01.017_bib1340","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"Ndjeka","year":"2015","journal-title":"Int J Tuberc Lung Dis."},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1345","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1128\/AAC.00191-13","article-title":"Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis","volume":"57","author":"Svensson","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"10.1016\/j.lpm.2017.01.017_bib1350","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1128\/AAC.03246-14","article-title":"Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection","volume":"58","author":"Svensson","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"10.1016\/j.lpm.2017.01.017_bib1355","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1128\/AAC.00509-16","article-title":"Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects","volume":"60","author":"Mallikaarjun","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.lpm.2017.01.017_bib1360","first-page":"779","article-title":"The role of delamanid in the treatment of drug-resistant tuberculosis","volume":"11","author":"Lewis","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.lpm.2017.01.017_bib1365","unstructured":"Clinical Trials Gov NCT02333799. https:\/\/clinicaltrials.gov accessed 23rd\u00a0October\u00a02016."},{"issue":"2","key":"10.1016\/j.lpm.2017.01.017_bib1370","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/13993003.01330-2015","article-title":"Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis","volume":"47","author":"Siwendu","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib1375","unstructured":"Conradie F, Diacon A, Mendel C, Everitt D, Van Niekerk C, Howell P, et al. Interim results of nix-TB clinical study of pretomanid, bedaquiline and linezolid for treatment of XDR and treatment intolerant\/failed MDR TB. OA-3117 presented at the 47th Union World Conference on Lung Health. Liverpool, UK: 26\u00a0October \u2013 29\u00a0October\u00a02016."},{"key":"10.1016\/j.lpm.2017.01.017_bib1380","article-title":"Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers","author":"Alffenaar","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.lpm.2017.01.017_bib1385","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.lpm.2017.01.017_bib1390","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.lpm.2017.01.017_bib1395","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest."},{"key":"10.1016\/j.lpm.2017.01.017_bib1400","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2017.01.017_bib1405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600mg\/day versus efavirenz 800mg\/day in HIV infected patients with tuberculosis receiving rifampicin: 48\u00a0weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.lpm.2017.01.017_bib1410","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/518655","article-title":"Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome","volume":"196","author":"McIlleron","year":"2007","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.lpm.2017.01.017_bib1415","first-page":"1","article-title":"Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors","volume":"53","year":"2004","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.lpm.2017.01.017_bib1420","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jac\/dkq540","article-title":"Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis","volume":"66","author":"Mena","year":"2011","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1425","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins","volume":"53","author":"Regazzi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lpm.2017.01.017_bib1430","doi-asserted-by":"crossref","DOI":"10.1097\/QCO.0b013e32832d7aff","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients","volume":"22","author":"Sun","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1435","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","article-title":"Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS","volume":"158","author":"Narita","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1440","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/civ978","article-title":"Robust reconstitution of tuberculosis-specific polyfunctional CD4+ T-cell responses and rising systemic interleukin\u00a06 in paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"62","author":"Ravimohan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1445","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1473-3099(15)70008-3","volume":"15","author":"Ravimohan","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.017_bib1450","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000000030","article-title":"Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity and implications for HIV-TB programs","volume":"65","author":"Luetkemeyer","year":"2014","journal-title":"J Acquired Immune Def Syndr 1999"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1455","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2325957415599210","article-title":"The effect of early initiation of antiretroviral therapy in TB\/HIV-coinfected patients: a systematic review and meta-analysis","volume":"14","author":"Abay","year":"2015","journal-title":"J Int Assoc Prov AIDS Care"},{"key":"10.1016\/j.lpm.2017.01.017_bib1460","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jctube.2016.03.002","article-title":"Tuberculosis-immune reconstitution inflammatory syndrome","volume":"3","author":"Lanzafame","year":"2016","journal-title":"J Clin Tubercul Mycobact Dis"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.017_bib1465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/sti.2005.017863","article-title":"Montelukast in the treatment of HIV associated immune reconstitution disease","volume":"82","author":"Hardwick","year":"2006","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.lpm.2017.01.017_bib1470","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib1475","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/650531","article-title":"Recurrent tuberculosis-relapse, re-infection and HIV","volume":"201","author":"Chaisson","year":"2010","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib1480","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1086\/650528","article-title":"Impact of HIV infection on the recurrence of tuberculosis in South India","volume":"201","author":"Narayanan","year":"2010","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.017_bib1485","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1086\/650529","article-title":"High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis","volume":"201","author":"Glynn","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1490","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1473-3099(03)00607-8","article-title":"Recurrence in tuberculosis: relapse or reinfection","volume":"3","author":"Lambert","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1500","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJM199404283301702","article-title":"The effect of directly observed therapy on the rates of drug resistance and relapse of tuberculosis","volume":"330","author":"Weis","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.017_bib1505","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/pmj.76.895.259","article-title":"Impact of HIV infection on tuberculosis","volume":"76","author":"Zumla","year":"2000","journal-title":"Postgrad Med J BMJ J"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.017_bib1510","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/infdis\/jiu574","article-title":"Recurrence due to relapse or reinfection with mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up","volume":"211","author":"Guerra-Assun\u00e7\u00e3o","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.017_bib1515","article-title":"Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union","author":"van der Werf","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib1520","article-title":"Applicability of World Health Organization's recommended new shorter regimen in an MDR-TB high burden country","author":"Javaid","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.017_bib1525","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","author":"L\u00f6nnroth","year":"2015","journal-title":"ERJ Express"},{"key":"10.1016\/j.lpm.2017.01.017_bib1530","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821730057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821730057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T01:05:30Z","timestamp":1568855130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075549821730057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S075549821730057X"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.017","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cursed duet today: Tuberculosis and HIV-coinfection","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}